Immunovia Successfully Develops Assays to Measure Targeted Proteins for Its Next-generation Pancreatic Cancer Test - Moving Forward Towards Model-development Study
Immunovia Successfully Develops Assays to Measure Targeted Proteins for Its Next-generation Pancreatic Cancer Test - Moving Forward Towards Model-development Study
LUND, Sweden, April 9, 2024 /PRNewswire/ -- Immunovia (NASDAQ: IMMNOV) (STO: IMMNOV), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, announces today that the company has successfully developed accurate and precise assays to measure targeted proteins for its next-generation test.
瑞典隆德，2024年4月9日 /PRNewswire/ — 以通過早期發現提高胰腺癌存活率爲使命的診斷公司Immunovia（納斯達克股票代碼：IMMNOV）（STO：IMMNOV）今天宣佈，該公司已成功開發出準確而精確的檢測方法，用於測量其下一代測試的靶向蛋白。
As announced in November 2023, Immunovia successfully finalized a discovery study that evaluated nearly 3,000 proteins to identify 15 promising protein biomarkers for its next-generation test to detect early-stage pancreatic cancer.
正如2023年11月宣佈的那樣，Immunovia成功完成了一項發現性研究，該研究評估了近3,000種蛋白質，爲其下一代早期胰腺癌檢測測試確定了15種有前途的蛋白質生物標誌物。
As the next milestone in developing its next-generation test Immunovia, in collaboration with the company's research and development partner Proteomedix (an Onconetix company), has developed accurate and reliable assays to measure the most promising proteins identified in the discovery study to move forward to a model-development study.
作爲開發下一代測試的下一個里程碑，Immunovia與該公司的研發合作伙伴Proteomedix（一家Onconetix公司）合作，開發了準確可靠的檢測方法，以測量發現研究中發現的最有前途的蛋白質，以推進模型開發研究。
The newly developed assays leverage commercial reagents and an automated, high-throughput ELISA testing platform. By moving from the proprietary IMMray platform used for Immunovia's prior test, IMMray PanCan-d, to the widely used commercial ELISA platform, Immunovia expects to substantially reduce lead-time in production as well as cost of goods sold for its next generation test.
新開發的檢測方法利用了商用試劑和自動化的高通量 ELISA 測試平台。通過從用於Immuvia先前測試的專有ImmRay平台ImmRay PanCan-D轉移到廣泛使用的商用ELISA平台，Immuvia預計將大幅縮短生產週期，並降低其下一代測試的銷售成本。
"Successfully developing assays to measure the promising protein biomarkers is a critical step in developing our next-generation test. The team's pace in developing the assays was tremendous. Leveraging the ELISA platform enabled us to move quickly and will also lower our future testing costs," said Jeff Borcherding, Immunovia CEO.
“成功開發用於測量有前景的蛋白質生物標誌物的測定方法是開發下一代測試的關鍵步驟。該團隊開發化驗的速度非常快。利用ELISA平台使我們能夠快速採取行動，也將降低我們未來的測試成本。” Immunovia首席執行官傑夫·博徹丁說。
Immunovia is currently conducting a model-development study for the next-generation test in which it will select the highest performing biomarkers to include in the test, define the algorithm to produce a diagnostic result, and provide an initial assessment of the test's clinical performance (i.e., sensitivity and specificity). As previously communicated, the company expects to release the results of the model development study early in Q2 2024.
Immunovia目前正在爲下一代測試進行模型開發研究，在該研究中，它將選擇性能最高的生物標誌物納入測試，定義生成診斷結果的算法，並對該測試的臨床表現（即靈敏度和特異性）進行初步評估。如前所述，該公司預計將在2024年第二季度初發布模型開發研究的結果。
For more information, please contact:
欲了解更多信息，請聯繫：
Jeff Borcherding
CEO and President
[email protected]
傑夫·博徹丁
首席執行官兼總裁
[電子郵件保護]
Karin Almqvist Liwendahl
Chief Financial Officer
[email protected]
+46 709 11 56 08
Karin Almqvist Liwendahl
首席財務官
[電子郵件保護]
+46 709 11 56 08
Immunovia in brief
Immunovia 簡介
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia AB是一家診斷公司，其使命是通過早期發現提高胰腺癌患者的存活率。Immunovia專注於簡單的血液檢測的開發和商業化，以檢測表明高危人群患上胰腺癌的蛋白質和抗體。
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia與醫療保健提供者、領先的專家和患者權益團體合作和互動，向胰腺癌風險較高的人群提供其檢測。
USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
美國是世界上最大的胰腺癌檢測市場。該公司估計，在美國，有180萬人面臨胰腺癌的高風險，並可能受益於年度監測測試。
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit
Immunovia的股票（IMMNOV）在斯德哥爾摩納斯達克上市。欲了解更多信息，請訪問
This information was brought to you by Cision
這些信息是由 Cision 帶給你的
The following files are available for download:
以下文件可供下載：
|
Press release (PDF) |
|
新聞稿 (PDF) |
SOURCE Immunovia AB
來源 Immunovia AB
譯文內容由第三人軟體翻譯。